About Le-vanza Pharma
Le-vanza Pharma offers products and services including Injections and Capsules and Soft Gels.
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Legal Name Le-Vanza Pharma Pvt. Ltd
- Date of Incorporation 12 Jan, 2009
- Jurisdiction Chandigarh, India
- Annual Revenue₹4.42 Cr
FY 2025 · -6% YoY
- Net Profit₹3.1 Lakh
FY 2025 · 1% margin
- EBITDA₹19.4 Lakh
FY 2025 · 4% margin
Associated legal entities of Le-vanza Pharma
Le-vanza Pharma operates through Le - Vanza Pharma Private Limited (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2025) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Le - Vanza Pharma Private Limited CIN U24232CH2009PTC031483 | Active | 12 Jan 2009 | Chandigarh, Chandigarh | ₹4.4 Cr | – | 2 | View details |
Products & Services of Le-vanza Pharma
Le-vanza Pharma offers a comprehensive portfolio of products and services, including Injections and Capsules and Soft Gels.
Injections are manufactured and distributed as part of the pharmaceutical offerings for healthcare applications
Capsules and soft gels are produced and supplied within the range of medicines aimed at various health needs
Board of directors of Le - Vanza Pharma Private Limited (Le-vanza Pharma)
Le - Vanza Pharma Private Limited is the primary company behind Le-vanza Pharma. The board of Le - Vanza Pharma Private Limited currently have 2 directors; the longest-serving is Krishan Dev Arora, appointed in 2009. 2 earlier directors have ceased.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Krishan Dev Arora DIN 01444008 | Director | 12 Jan 2009 | 17 yrs 8 mo | Le - Vanza Pharma Private Limited |
| Sherif Arora DIN 09112616 | Director | 05 Feb 2022 | 4 yrs 8 mo | Le - Vanza Pharma Private Limited |
Financials of Le-vanza Pharma
Figures of Le - Vanza Pharma Private Limited, the primary company behind Le-vanza Pharma, for FY 2025. Revenue was ₹4.42 Cr (-6% year on year). Net profit was ₹3.1 Lakh (1% margin). EBITDA was ₹19.4 Lakh (4% margin). Revenue has grown at a compounded annual rate of +2% over three years and +2% over five years.
- ₹4.42 CrRevenue · FY 2025 · -6% YoY
- ₹3.1 LakhNet profit · 1% margin
- ₹19.4 LakhEBITDA · 4% margin
- ₹25 LakhPaid-up capital
- +2%Revenue CAGR, 3 years
- +2%Revenue CAGR, 5 years
Balance sheet, profit and loss, cash flow and ratios of Le - Vanza Pharma Private Limited are on its company page.
Detailed financial statements for Le-vanza Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Similar companies to Le-vanza Pharma
10 companies that operate in the same segment as Le-vanza Pharma (Pharmaceuticals & Distribution), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Pharmaceutical products are manufactured and marketed worldwide. | 1891 | Kenilworth, Warwickshire, United Kingdom | – | USD 64.93 B | 781 | |
Therapeutics for neurology, oncology, rare, and endocrinology diseases are developed. | 2014 | New York, New York, United States | USD 1.3 B | USD 8.26 M | 750 | |
Developer of pharmaceutical products for treating multiple diseases | 1980 | Thousand Oaks, California, United States | – | USD 33.23 B | 28,000 | |
Biopharmaceutical research and drug development are conducted globally by AbbVie. | 2012 | Chicago, Illinois, United States | – | USD 61.16 B | 55,000 | |
Traditional pharmaceutical medicines are developed for multiple health fields. | 1876 | United States | – | USD 65.18 B | 47,000 | |
Developer of medicines to treat HIV/AIDS, liver diseases, cancer & others | 1987 | Foster City, California, United States | – | USD 29.45 B | 17,600 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
Treatments for anemia and fibrosis by exploiting connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. | 1993 | San Francisco, California, United States | USD 215.5 M | USD 29.62 M | 225 | |
Developer of medical devices, generic pharmaceuticals, and nutrition products | 1888 | Libertyville, Illinois, United States | – | USD 44.33 B | 3,710 | |
Medicines and health products are retailed through pharmacy outlets. | 2006 | Hyderabad, Telangana, India | USD 268.78 M | USD 734.57 M | 25,010 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Le-vanza Pharma
The primary company behind Le-vanza Pharma, Le - Vanza Pharma Private Limited, reported revenue of ₹4.42 Cr for FY 2025, down 6% year on year.
Le-vanza Pharma is recognized as an integrated pharmaceutical company that was established in 2008, drawing on expertise from Indian and multinational pharmaceutical experiences. A wide array of quality, affordable medicines is provided by the company, which is trusted by healthcare professionals across India. The focus is placed on developing innovative products to enhance human health, with ethical standards being maintained to ensure societal betterment without compromise. Responsibility for improving life quality through accessible healthcare solutions is emphasized, alongside a commitment to innovations that support global health improvements.
Le-vanza Pharma offers Injections and Capsules and Soft Gels.
Le-vanza Pharma operates through Le - Vanza Pharma Private Limited.
The legal entities of Le-vanza Pharma currently have 2 directors, including Sherif Arora, Krishan Dev Arora.